<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567774</url>
  </required_header>
  <id_info>
    <org_study_id>198/2012/D</org_study_id>
    <nct_id>NCT01567774</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy
      (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events.

      Levels of platelet reactivity in patients on DAT can be influenced by concomitant treatment
      with medications that inhibit the CYP3A4 system involved in the activation of clopidogrel.

      Atorvastatin and simvastatin are metabolized by CYP3A4 [Clin pharmacokinetic 2002; 41:
      343-70], whereas the cytochrome P450 mediated metabolism of rosuvastatin appears to be
      minimal and principally mediated by the 2C9 isoenzyme, with little involvement of CYP3A4
      [Clin Ther 2003; 25: 2822-5.].

      Previous studies comparing atorvastatin versus rosuvastatin by means of ex vivo platelet
      function tests have yielded conflicting results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 1 month after starting DAT (clopidogrel 75 mg and aspirin 100 mg), patients will
      receive randomly atorvastatin (20 mg day, N=50) or rosuvastatin (10 mg bid, N=50) for 30 days
      (until T-1).

      At this time-point, there will be a wash-out period of 15 days after the first treatment with
      atorvastatin or rosuvastatin in order to avoid any carry-over effect.

      Afterwards, a cross-over will be performed, and patients will be switched to the other drug
      which will be continued for further 30 days (until T-2).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of platelet reaction units</measure>
    <time_frame>After 30 days of treatment with each drug</time_frame>
    <description>Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of high platelet reactivity</measure>
    <time_frame>After 30 days of treatment with each drug</time_frame>
    <description>Frequency of high platelet reactivity with the 2 study treatments (as defined by a Platelet Reaction Unit value&gt;240</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive randomly atorvastatin (20 mg day) for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive randomly rosuvastatin (10 mg per day) for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>os, 20 mg, once per day, for 30 days</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Norvasc, Pfizer, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>os, 10 mg, once per day, for 30 days</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor, AstraZeneca, UK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographically-proven coronary artery disease

          -  Class I indication to DAT because of recent (&lt;12 months) percutaneous coronary
             intervention and/or recent acute coronary syndrome (&lt;12 months)

          -  Stable clinical conditions

          -  Able to understand and willing to sign the informed CF

        Exclusion Criteria:

          -  Use of other drug interfering with CYP activity such as proton pump inhibitors

          -  Women of child bearing potential patients must demonstrate a negative pregnancy test
             performed within 24 hours before CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Pelliccia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+39064997</phone>
    <phone_ext>123</phone_ext>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+39064997</phone>
    <phone_ext>123</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sapienza University</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pelliccia, MD</last_name>
      <phone>064997</phone>
      <phone_ext>123</phone_ext>
      <email>f.pelliccia@mclink.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Pelliccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00166</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Pelliccia, MD</last_name>
      <phone>+3906499</phone>
      <phone_ext>123</phone_ext>
      <email>f.pelliccia@mclink.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

